Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Apr;45(2):437-442.
doi: 10.19852/j.cnki.jtcm.2025.02.009.

Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial

Affiliations
Randomized Controlled Trial

Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial

Nima Vaziri et al. J Tradit Chin Med. 2025 Apr.

Abstract

Objective: To evaluate the effect of this plant as adjunctive therapy on Helicobacter pylori (H. pylori) eradication.

Methods: The plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with H. pylori infection were randomized to receive Salvia mirzayanii Rech. f. & Esfand (S. mirzayanii) or placebo capsules for two weeks. All the patients in both groups received clarithromycin-based triple therapy. Both intention to treat and per protocol analyses were performed. Eradication rates, treatment side effects, and medication compliance were evaluated in both groups.

Results: H. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of H. pyloriwas significantly higher in S. mirzayanii group compared with that in the placebo group for per protocol analysis (84.62%, P = 0.026) but not for intention to treat one (65.31%, P = 0.252). There were no significant differences between the two groups regarding the frequencies of the medications side effects and the patients with poor compliance.

Conclusion: The use of S. mirzayanii as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve H. pylorieradication rate.

Keywords: Rech. f. & Esfand; clarithromycin-based triple therapy; resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The CONSORT flow diagram for the study participants

Similar articles

References

    1. Fakheri H, Firoozi MS, Bari Z. Eradication of Helicobacter pylori in Iran: a review. Middle East J Dig Dis 2018; 10: 5-17. - PMC - PubMed
    1. Keikha M, Askari P, Ghazvini K, Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and Meta-analysis. J Glob Antimicrob Resist 2021; 29: 420-9. - PubMed
    1. Abou Baker D. Plants against Helicobacter pylori to combat resistance: an ethnopharmacological review. Biotechnol Rep 2020; 26: e00470. - PMC - PubMed
    1. Zahid R, Akram M, Riaz M, Munir N, Shehzad M. Phytotherapeutic modalities for the management of Helicobacter pylori associated peptic ulcer. Eur J Inflamm 2020; 18: 1-16.
    1. Askari SF, Avan R, Tayarani-Najaran Z, Sahebkar A, Eghbali S. Iranian Salvia species: a phytochemical and pharmacological update. Phytochemistry 2021; 183: 112619. - PubMed

Publication types

LinkOut - more resources